DrugPatentWatch Database Preview
Drugs in Development Information for Gossypol
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Gossypol?
Gossypol is an investigational drug.
There have been 10 clinical trials for Gossypol.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Glioblastoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Sidney Kimmel Comprehensive Cancer Center.
There are seven hundred and eighty-three US patents protecting this investigational drug and five international patents.
Summary for Gossypol
| US Patents | 783 |
| International Patents | 5,106 |
| US Patent Applications | 1,404 |
| WIPO Patent Applications | 977 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2013-09-01) |
| Vendors | 81 |
Recent Clinical Trials for Gossypol
| Title | Sponsor | Phase |
|---|---|---|
| R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | Mayo Clinic | Phase 1/Phase 2 |
| Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Gossypol
Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol
US Patents for Gossypol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Gossypol | Start Trial | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | Start Trial |
| Gossypol | Start Trial | Pyrazol-3-ones that activate pro-apoptotic BAX | Dana-Farber Cancer Institute, Inc. (Boston, MA) | Start Trial |
| Gossypol | Start Trial | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | Dana-Farber Cancer Institute, Inc. (Boston, MA) | Start Trial |
| Gossypol | Start Trial | Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor | The Regents of the University of California (Oakland, CA) | Start Trial |
| Gossypol | Start Trial | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | Start Trial |
| Gossypol | Start Trial | Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy | University of Georgia Research Foundation Inc. (Athens, GA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Gossypol
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Gossypol | Australia | 2014232383 | 2033-03-15 | Start Trial |
| Gossypol | Australia | 2019202731 | 2033-03-15 | Start Trial |
| Gossypol | Brazil | 112015023267 | 2033-03-15 | Start Trial |
| Gossypol | Canada | 2906931 | 2033-03-15 | Start Trial |
| Gossypol | Canada | 3046894 | 2033-03-15 | Start Trial |
| Gossypol | China | 105142635 | 2033-03-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
